D. E. Shaw & Co. Inc. grew its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 220.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 442,070 shares of the company's stock after buying an additional 304,003 shares during the period. D. E. Shaw & Co. Inc. owned 0.56% of Viridian Therapeutics worth $8,474,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in VRDN. Barclays PLC increased its stake in shares of Viridian Therapeutics by 113.1% in the 3rd quarter. Barclays PLC now owns 125,397 shares of the company's stock valued at $2,851,000 after purchasing an additional 66,550 shares in the last quarter. SG Americas Securities LLC grew its holdings in shares of Viridian Therapeutics by 89.1% during the 4th quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock worth $596,000 after purchasing an additional 14,644 shares during the period. Moody Aldrich Partners LLC purchased a new position in shares of Viridian Therapeutics during the 4th quarter worth approximately $1,125,000. Vanguard Group Inc. raised its holdings in shares of Viridian Therapeutics by 4.0% in the 4th quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after buying an additional 174,952 shares during the period. Finally, Principal Financial Group Inc. increased its stake in Viridian Therapeutics by 3.3% during the fourth quarter. Principal Financial Group Inc. now owns 178,444 shares of the company's stock worth $3,421,000 after purchasing an additional 5,634 shares during the period.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on VRDN shares. Royal Bank of Canada decreased their target price on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and set a $34.00 price target on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. JMP Securities dropped their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group reduced their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $36.70.
Check Out Our Latest Analysis on VRDN
Viridian Therapeutics Trading Down 1.1%
Shares of Viridian Therapeutics stock traded down $0.15 during trading hours on Wednesday, reaching $13.67. The stock had a trading volume of 181,308 shares, compared to its average volume of 1,189,643. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $27.20. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -3.16 and a beta of 0.57. The firm has a 50 day simple moving average of $13.29 and a two-hundred day simple moving average of $17.01.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.08. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. Viridian Therapeutics's revenue for the quarter was up .0% compared to the same quarter last year. As a group, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.
About Viridian Therapeutics
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
See Also
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
